Compare WATT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | LEXX |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Canada |
| Employees | 26 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 18.9M |
| IPO Year | 2014 | N/A |
| Metric | WATT | LEXX |
|---|---|---|
| Price | $8.67 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 520.8K | 204.6K |
| Earning Date | 02-26-2026 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | $522,000.00 |
| Revenue This Year | $509.64 | $13.35 |
| Revenue Next Year | $210.44 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | 5.05 |
| 52 Week Low | $3.62 | $0.46 |
| 52 Week High | $18.36 | $1.91 |
| Indicator | WATT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 75.36 | 42.82 |
| Support Level | $6.75 | $0.71 |
| Resistance Level | $9.62 | $0.80 |
| Average True Range (ATR) | 0.76 | 0.07 |
| MACD | 0.32 | 0.00 |
| Stochastic Oscillator | 85.90 | 16.89 |
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.